EXACERBATIONS AND REAL-WORLD OUTOMES AMONG PATIENTS WITH COPD INITIATING BREZTRI (EROS+CP Japan Study) - EROS+CP-Japan

Inclusion Criteria

• -Diagnosis of COPD (at any position) before or on the index date
• -≥ 1 dispensation of BGF on or following the launch date of BGF in Japan
• -Patients must have evidence of at least one qualifying COPD exacerbation event, which qualify the initiation of triple therapy. The exacerbation event must occur within the 12-month period preceding BGF initiation and on or after BGF launch in Japan (i.e., 04 September 2019). The earliest qualifying COPD exacerbation event will be set as the index date.
• -≥ 12 months of continuous health plan enrollment preceding the qualifying COPD exacerbation date
• -≥ 1 day of continuous enrollment following the qualifying COPD exacerbation date
• -Age ≥ 40 years on the qualifying COPD exacerbation date